BioSpecifics Technologies Corp (BSTC)
(Delayed Data from NSDQ)
$66.72 USD
+0.21 (0.32%)
Updated May 3, 2019 04:00 PM ET
After-Market: $66.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.72 USD
+0.21 (0.32%)
Updated May 3, 2019 04:00 PM ET
After-Market: $66.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) Vyxeos receives marketing approval from the European Commission for treating acute myeloid leukemia.
Ironwood's Linzess Gets Approval in Japan for New Indication
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) along with its partner Astellas Pharma announces approval of Linzess in Japan for a new indication - chronic constipation.
VIVUS' (VVUS) Qsymia Falters in a Highly Competitive Market
by Zacks Equity Research
VIVUS' (VVUS) Qsymia sales lackluster due to slow uptake of the drug and a competitive market.
Lannett Set to Lose Distribution Agreement With Key Supplier
by Zacks Equity Research
Lannett Company's (LCI) distribution agreement with key supplier, Jerome Stevens Pharmaceuticals, not to be renewed on expiry. Shares plunge.
Zacks.com highlights: PCM, STAAR Surgical, Verso, Johnson Outdoors and BioSpecifics Technologies
by Zacks Equity Research
Zacks.com highlights: PCM, STAAR Surgical, Verso, Johnson Outdoors and BioSpecifics Technologies
5 Stocks With Recent Price Strength to Enhance Your Returns
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
BioSpecifics Technologies (BSTC) Q2 Earnings Top Estimates
by Zacks Equity Research
BioSpecifics (BSTC) delivered earnings and revenue surprises of 20.41% and -0.06%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Can The Uptrend Continue for BioSpecifics Technologies (BSTC)?
by Zacks Equity Research
BioSpecifics Technologies Corp. (BSTC) has been on the move lately as the stock has risen by 8.7% in the past four weeks
Valeant Pharmaceuticals (VRX) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
Valeant Pharmaceuticals (VRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
What Falling Estimates & Price Mean for Adamis Pharmaceuticals (ADMP)
by Zacks Equity Research
Adamis Pharmaceuticals (ADMP) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 12.9% in Session
by Zacks Equity Research
Pacira Pharmaceuticals (PCRX) was a big mover last session, as the company saw its shares rise more than 12% on Friday amid huge volumes.
Falling Earnings Estimates Signal Weakness Ahead for Karyopharm Therapeutics (KPTI)
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
Why Flexion Therapeutics (FLXN) Could Be Positioned for a Slump
by Zacks Equity Research
Flexion Therapeutics (FLXN) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
Aratana Therapeutics (PETX) Soars: Stock Adds 12.4% in Session
by Zacks Equity Research
Aratana Therapeutics (PETX) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.
Madrigal Pharmaceuticals (MDGL) Soars: Stock Adds 6.5% in Session
by Zacks Equity Research
Madrigal Pharmaceuticals (MDGL) was a big mover last session, as the company saw its shares rise more than 6% on the day.
Nektar (NKTR) Surges: Stock Moves 11% Higher
by Zacks Equity Research
Nektar (NKTR) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
ImmunoGen (IMGN) Soars: Stock Adds 10.3% in Session
by Zacks Equity Research
ImmunoGen (IMGN) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
RedHill Biopharma (RDHL) in Focus: Stock Moves 10.2% Higher
by Zacks Equity Research
RedHill Biopharma (RDHL) was a big mover last session, as the company saw its shares rise more than 10% on the day.
New Strong Sell Stocks for December 6th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for December 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for November 27th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
New Strong Sell Stocks for November 22nd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
New Strong Sell Stocks for November 17th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for September 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for September 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: